On January 24, 2022, NC State Health Director, Dr. Betsey Cuervo Tilson, rescinded the statewide standing orders for the following due to the high prevalence of the Omicron variant of the SARS-CoV-2 virus in North Carolina for which these therapies are not an effective treatment:
- Subcutaneous Administration of Casirivimab/ Imdevimab (REGEN-COV) Monoclonal Antibodies
- Intravenous Administration of Casirivimab/ Imdevimab (REGEN-COV) Monoclonal Antibodies
- Intravenous Administration of Bamlanivimab/ Etesevimab Monoclonal Antibodies
The order for Sotrovimab remains in effect, with important patient triage prioritization given the limited supply of this therapy.
